Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Compugroup Medical SE    COP   DE0005437305

Real-time Quote. Real-time Tradegate - 05/24 09:29:00 pm
38.15 EUR   +1.42%
05/19 COMPUGROUP MEDI : ex-dividend day for annual dividend
05/04 COMPUGROUP MEDI : First Quarter Results 2016
02/11 ASPYRA : February 2016 Tech Guide: LIS and LIMS
Analysis summary4-Traders Strategies 

CompuGroup Medical AG : Benefit from the uptrend

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2013 | 11:01am
Opinion : Bullish above EUR 15.2
Target price : EUR 17
Stop loss: EUR 14.7

CompuGroup Medical continues its bullish trend in order to test new highest level.

The company’s fundamentals are still strong. Sales are up 13.9% for one year. Analysts from Thomson Reuters consensus have revised largely upward their EPS estimates.

From a technical point of view, the share price is trading in a bullish trend on both short and on long term time scales. However, the buyer consensus seems to need to blow a little and a return on 20-day moving average is not excluded.

A decrease to the EUR 15.5 area allow a remobilization of a bullish consensus and then targeting a return to EUR 17 before revealing new targets upward in case of exceeding this level. The stop loss is set below EUR 15.2 short-term support.

CompuGroup Medical AG : CompuGroup Medical AG : Benefit from the uptrend

© Zonebourse.com 2013

share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: 4-traders.com is a website published by SURPERFORMANCE SAS. Surperformance or 4-traders.com is not a registered broker-dealer nor a registered investment adviser. You understand that this web site and its content is furnished for your personal, noncommercial, informational purposes only, and that no mention of a particular security in this website constitutes a recommendation to buy, sell, or hold any other security, nor that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Surperformance and 4-traders.com services will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. Information regarding trading and investment as provided by Surperformance professional is not tailored to the investment needs of any specific person. You acknowledge that you are responsible for your own financial decisions and should seek a registered financial agent depending on your own risk tolerance to advise you on your personal trading activities.

Financial Ratios

Size 2016e 2017e
Capitalization 1 926 M€ -
Entreprise Value (EV) 2 219 M€ 2 168 M€
Valuation 2016e 2017e
P/E ratio (Price / EPS) 34,2x 27,1x
Capitalization / Revenue 3,33x 3,03x
EV / Revenue 3,83x 3,41x
EV / EBITDA 16,8x 14,6x
Yield (DPS / Price) 1,18% 1,25%
Price to book (Price / BVPS) 8,09x 6,64x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 17,3% 18,5%
operating Leverage (Delta EBIT / Delta Sales) - 1,78x
Net Margin (Net Profit / Revenue) 9,58% 10,6%
ROA (Net Profit / Asset) 8,15% 9,50%
ROE (Net Profit / Equities) 27,8% 28,3%
Rate of Dividend 40,4% 34,0%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   2,77% 2,66%
Cash Flow / Sales 15,6% 15,6%
Capital Intensity (Assets / Sales) 1,17x 1,11x
Financial Leverage (Net Debt / EBITDA) 2,22x 1,63x
Income Statement Evolution
More Financials
EPS Revisions